Bellevue Life Sciences Acquisition Corp. Rights
BLACR
BLACR was delisted on the 14th of February, 2025.
24 hedge funds and large institutions have $1.2M invested in Bellevue Life Sciences Acquisition Corp. Rights in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
45% more capital invested
Capital invested by funds: $833K → $1.2M (+$371K)
9% more funds holding
Funds holding: 22 → 24 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$116K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$30.8K |
| 3 |
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Harrisburg,
Pennsylvania
|
+$19.7K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$999 |
| 5 |
CS
Clear Street
New York
|
+$156 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$5.06K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$39 |
BLACR Hedge Fund Activity: Q3 2023 in Review
24 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Rights (BLACR) for Q3 2023, worth a combined $1.2M — up 45% from $833K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BLACR positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Periscope Capital, adding an estimated $116K. The largest seller was Citadel Advisors, exiting entirely with an estimated $5.06K sold.
- 24 institutional investors held Bellevue Life Sciences Acquisition Corp. Rights (BLACR) as of Q3 2023, up from 22 in Q2 2023.
- Funds reported $1.2M of Bellevue Life Sciences Acquisition Corp. Rights stock for Q3 2023, up 45% quarter-over-quarter.
- 3 funds opened new Bellevue Life Sciences Acquisition Corp. Rights positions in Q3 2023 and 1 closed out, a net change of +2 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Rights buyer in Q3 2023 was Periscope Capital, an estimated $116K added.
- The largest Bellevue Life Sciences Acquisition Corp. Rights seller in Q3 2023 was Citadel Advisors, an estimated $5.06K sold.
Based on aggregated 13F filings for Q3 2023.